Isbel Snchez-Prez

List of Publications by Year in Descending Order

42 papers	1,998 citations	22 h-index	44 g-index
44 ext. papers	2,179 ext. citations	7.3 avg, IF	4.3 L-index

#	Paper	IF	Citations
42	Therapeutic efficiency of the APAF-1 antagonist LPT99 in a rat model of cisplatin-induced hearing loss. *Clinical and Translational Medicine*, **2021**, 11, e363	5.7	2
41	Targeting MAD2 modulates stemness and tumorigenesis in human Gastric Cancer cell lines. *Theranostics*, **2020**, 10, 9601-9618	12.1	7
40	P53 pathway is a major determinant in the radiosensitizing effect of Palbociclib: Implication in cancer therapy. *Cancer Letters*, **2019**, 451, 23-33	9.9	29
39	Deficit of mitogen-activated protein kinase phosphatase 1 (DUSP1) accelerates progressive hearing loss. *ELife*, **2019**, 8,	8.9	11
38	The angiotensin-(1-7)/Mas receptor axis protects from endothelial cell senescence via klotho and Nrf2 activation. *Aging Cell*, **2019**, 18, e12913	9.9	41
37	New Findings in the Signaling Pathways of and Platinum Iodido ComplexesUnteraction with DNA of Cancer Cells. *ACS Omega*, **2019**, 4, 21855-21861	3.9	3
36	Using phosphine ligands with a biological role to modulate reactivity in novel platinum complexes. *Royal Society Open Science*, **2018**, 5, 171340	3.3	6
35	The human PKP2/plakophilin-2 gene is induced by Wnt/Ecatenin in normal and colon cancer-associated fibroblasts. *International Journal of Cancer*, **2018**, 142, 792-804	7.5	21
34	XPA, XPC, and XPD Modulate Sensitivity in Gastric Cisplatin Resistance Cancer Cells. *Frontiers in Pharmacology*, **2018**, 9, 1197	5.6	9
33	In vivo FRET-FLIM reveals cell-type-specific protein interactions in Arabidopsis roots. *Nature*, **2017**, 548, 97-102	50.4	84
32	CHK1 expression in Gastric Cancer is modulated by p53 and RB1/E2F1: implications in chemo/radiotherapy response. *Scientific Reports*, **2016**, 6, 21519	4.9	27
31	Hepatitis C virus-mediated Aurora B kinase inhibition modulates inflammatory pathway and viral infectivity. *Journal of Hepatology*, **2015**, 63, 312-9	13.4	12
30	Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance. *Oncotarget*, **2015**, 6, 15551-65	3.3	38
29	Mad2 and BubR1 modulates tumourigenesis and paclitaxel response in MKN45 gastric cancer cells. *Cell Cycle*, **2014**, 13, 3590-601	4.7	33
28	E1a promotes c-Myc-dependent replicative stress: implications in glioblastoma radiosensitization. *Cell Cycle*, **2014**, 13, 52-61	4.7	7
27	Targeting Chk2 improves gastric cancer chemotherapy by impairing DNA damage repair. *Apoptosis: an International Journal on Programmed Cell Death*, **2013**, 18, 347-60	5.4	16
26	Reduced protein stability of human DJ-1/PARK7 L166P, linked to autosomal recessive Parkinson disease, is due to direct endoproteolytic cleavage by the proteasome. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2012**, 1823, 524-33	4.9	22

25	DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer. *Oncogene*, **2011**, 30, 668-78	9.2	60
24	Checkpoint kinase 1 modulates sensitivity to cisplatin after spindle checkpoint activation in SW620 cells. *International Journal of Biochemistry and Cell Biology*, **2010**, 42, 318-28	5.6	5
23	Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin. *Clinical Cancer Research*, **2009**, 15, 3530-9	12.9	50
22	Clinical impact of aneuploidy on gastric cancer patients. *Clinical and Translational Oncology*, **2009**, 11, 493-8	3.6	12
21	hCCR4/cNOT6 targets DNA-damage response proteins. *Cancer Letters*, **2009**, 273, 281-91	9.9	8
20	MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer. *Cancer Letters*, **2009**, 286, 206-16	9.9	19
19	A dyskerin motif reactivates telomerase activity in X-linked dyskeratosis congenita and in telomerase-deficient human cells. *Blood*, **2008**, 111, 2606-14	2.2	19
18	The role of the NFkappaB signalling pathway in cancer. *Clinical and Translational Oncology*, **2008**, 10, 143-7	3.6	46
17	Role of CHK2 in cancer development. *Clinical and Translational Oncology*, **2008**, 10, 538-42	3.6	28
16	Signalling pathways involved in clinical responses to chemotherapy. *Clinical and Translational Oncology*, **2007**, 9, 625-33	3.6	19
15	Human recombinant erythropoietin does not promote cancer growth in presence of functional receptors expressed in cancer cells. *Cancer Biology and Therapy*, **2007**, 6, 1600-5	4.6	13
14	DNA repair inhibitors in cancer treatment. *Clinical and Translational Oncology*, **2006**, 8, 642-6	3.6	33
13	The DASH complex and Klp5/Klp6 kinesin coordinate bipolar chromosome attachment in fission yeast. *EMBO Journal*, **2005**, 24, 2931-43	13	115
12	Subcellular localization determines the protective effects of activated ERK2 against distinct apoptogenic stimuli in myeloid leukemia cells. *Journal of Biological Chemistry*, **2004**, 279, 32813-23	5.4	48
11	Control of oncogenesis and cancer therapy resistance. *British Journal of Cancer*, **2004**, 90, 573-7	8.7	34
10	FK506 sensitizes mammalian cells to high osmolarity by modulating p38 MAP kinase activation. *Cellular and Molecular Life Sciences*, **2004**, 61, 700-8	10.3	9
9	The antidiabetic agent sodium tungstate activates glycogen synthesis through an insulin receptor-independent pathway. *Journal of Biological Chemistry*, **2003**, 278, 42785-94	5.4	35
8	The immunosuppressant FK506 uncovers a positive regulatory cross-talk between the Hog1p and Gcn2p pathways. *Journal of Biological Chemistry*, **2003**, 278, 33887-95	5.4	12

7	Schizosaccharomyces pombe essential genes: a pilot study. *Genome Research*, **2003**, 13, 399-406	9.7	61
6	Cell stress and MEKK1-mediated c-Jun activation modulate NFkappaB activity and cell viability. *Molecular Biology of the Cell*, **2002**, 13, 2933-45	3.5	89
5	Growth hormone protects against radiotherapy-induced cell death. *European Journal of Endocrinology*, **2002**, 147, 535-41	6.5	15
4	CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin. *Oncogene*, **2000**, 19, 5142-52	7.5	122
3	Lack of c-Jun activity increases survival to cisplatin. *FEBS Letters*, **1999**, 453, 151-8	3.8	84
2	Cisplatin induces a persistent activation of JNK that is related to cell death. *Oncogene*, **1998**, 16, 533-40	9.2	210
1	Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. *Genes and Development*, **1997**, 11, 463-75	12.6	484